Current research on treatments

New studies, expected in 2022:
1
. Study with biomarkers in healthy 18+ and people with depression or post-traumatic stress syndrome (Expected start : OKT 2022)
2. Study for people with uncontrolled depression (Expected start : DEC2022/JAN 2023)
3. Study for monoclonal antibodies to protect COVID-19 for people with weakened immune systems (Expected start : MAR2023)
Do you already wish to apply for more information for these planned projects without any obligation? Sign up here.

Current investigations with sufficient registrations

Innovative medicines
tested safely

The clinical phases of drug research begin with studies on healthy volunteers and patients. Here, researchers check whether the drug is effective against the disease and which doses are most suitable. Only when all the information is known can a pharmaceutical company register a drug as a medicine. Your participation in a study makes a difference!

Questions & answers

Frequently asked questions from our study participants

Do you have any questions about our investigations?

A clinical study with a new drug must always be conducted according to strict national and international rules and guidelines. The studies that take place at the ANIMA Research Centre are always submitted for approval to one of the Central Ethics Committees of the Flemish universities. Such a committee, consisting of highly specialised doctors, independently assesses whether the proposed study may proceed or not and under what conditions. To this end, they check whether:

  • we have built up our clinical research well and meaningfully
  • our clinical trials do not pose too many risks to the participants
  • we provide the right information to our participants
  • our participants voluntarily agree to participate

Participants sign a consent form confirming their approval to participate. This ensures your safety when participating in one of our studies.

National and international bodies check whether we strictly comply with the applicable rules and guidelines. For our centre, these include the Federal Agency for Medicines and Health Products (FAMHP), the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA).

These bodies carry out the required audits on a regular basis to ensure the safety of the participating patients and the integrity of the studies conducted.

Participation in a clinical study is always free of charge for the patient. Even if it is necessary to stay one night at the ANIMA Research Centre.
Depending on the study, the participant may or may not be reimbursed for his/her participation.

The research programmes carried out by Anima Research Centre are commissioned by internationally renowned pharmaceutical companies.

In terms of logistics, we are usually supported by the largest company in the world in this regard, IQVIA (formerly Quintiles).

The ARC Team is led by Managing Director and Principal Investigator Dr Erik Buntinx, psychiatrist. He has more than 25 years of experience as a Key Opinion Leader in global CNS drug development.

Our intensively trained research team of doctors, including 2 CNS specialists and 2 general practitioners with extensive clinical experience and a thorough knowledge of clinical factors, treat more than 600 patients per week.

Under the leadership of ARC's dedicated site manager Linde Buntinx, PhD in Bio-Medical Sciences, all our studies are coordinated and carried out according to the rules of the art.

All this, of course, ensures that when you participate in such a study, you have the best quality guarantees.

Before a patient can participate in a study with a new medicinal product, the physician in charge will carry out an examination of the patient's general health condition and will check whether the patient is eligible for the study.

From the moment the new medicine is taken, extensive medical examinations are carried out at regular intervals to check that the new medicine is safe and effective.

Depending on the study, several study days are planned during which the patient is examined in detail by a team of doctors and specialised nurses.

We find the right match

Targeted recruitment
& consent process

ARC can recruit patients from a detailed database of more than 10,000 patients with different pathologies. To this end, our research centre works closely with the Anima medical centre.

Through this database and our specific internal consent process, we are able to select the right patients based on their clinical characteristics (co-morbidities, medical history, attitude).

ARC has a proven track record of being the largest recruiting centre both nationally and internationally. For all recent studies, especially those in Ideopathic Hypersomnia and UTI vaccination, ARC has consistently been the European No. 1. Currently, ARC is the largest recruiter in the world for an ongoing study.

In all studies in which ARC participates, there is a high quality recruitment because of the in-house developed targeted recruitment and consent process that is explained in more detail in the chart.

January 1, 2019
Longlist

ARC can recruit patients from a detailed database of over 10,000 patients. We can also supplement this with referrals from surrounding doctors' practices and hospitals. We also have experience with advertising through (social) media. Patients who register are first extensively pre-screened via a medical questionnaire.

January 1, 2019
January 1, 2019
Shortlist

Thanks to this database and our specific internal consent process, we are able to preselect the right patients based on their clinical characteristics (co-morbidities, medical history, attitude).

January 1, 2019
January 1, 2019
Contact

The selected patients are then contacted by one of our doctors.
This is followed by a telephone call to set up an appointment.

January 1, 2019
January 1, 2019
Make an appointment

An appointment is made for the next step.

January 1, 2019
January 1, 2019
Informed consent process by (PI/Sub-PI)

The information and consent interview is always conducted by the PI or sub-PI of the clinical trial as defined in our internal procedure (SOP).

January 1, 2019
Safety first

Official controls & audits

These bodies carry out the required audits on a regular basis to ensure the safety of the participating patients and the integrity of the studies conducted.

Federal Agency for
Medicines and Health Products

European Medicines Agency (EMEA)

United States Food and Drug Administration

"Our patients are heroes. Thanks to their treatment research, we are improving the lives of many other people with the same condition.
You feel that, we are all going for the same goal."


Dr. Erik Buntinx, Psychiatrist
Founding CEO/ Principal Investigator

Do you have any questions about our investigations?

Patient testimonials

Our patients about Anima Research Center

Our pharmaceutical partners

Working together for a better world

Are you +60 years of age?
Is participating in a trial for an experimental RSV vaccine

More info on this study

News release about RSV

Scroll to Top